RARE CANCER RESEARCH FOUNDATION

RARE CANCER RESEARCH FOUNDATION

Durham, NC, US
•
501(c)3
•
EIN
46-3405526
•
WWW.RCRF.ORG

RARE CANCER RESEARCH FOUNDATION

Durham, NC, US
•
501(c)3
•
EIN
46-3405526
•
WWW.RCRF.ORG
Overview
Programs
990s
Income Statement
Balance Sheet
How to Apply
Sign up for more:
People
Board & Team
Financials
Financial Trends
Funding
Funders
Grants Received
Grantmaking
Giving Insights
Grantees
Grants Given
Overlap
Hide details

Programs

  • Program 1 [2020]
    PATTERN.ORG IS A GROUNDBREAKING PLATFORM THAT ALLOWS RCRF TO WORK DIRECTLY WITH CANCER PATIENTS ACROSS THE COUNTRY TO IDENTIFY PATIENTS ELIGIBLE TO DONATE TISSUE TO RESEARCH, EDUCATE THOSE PATIENTS ON RESEARCH OPPORTUNITIES, CONSENT THEM INTO SUCH RESEARCH PROGRAMS, AND THEN COORDINATE THE BIO-LOGISTICS OF MOVING THEIR TISSUE FROM THEIR LOCAL HOSPITALS TO WORLD-CLASS RESEARCH INSTITUTIONS. PATTERN.ORG WAS LAUNCHED WITH GREAT SUCCESS IN 2016, AND IN 2020, IN SPITE OF THE COVID-19 PANDEMIC SUCCESSFULLY DELIVERED HIGH QUALITY, VIABLE, LIVING RARE CANCER TISSUE FROM BOTH ACADEMIC AND COMMUNITY HOSPITALS ACROSS THE U.S. TO CRITICAL, INNOVATIVE RESEARCH INITIATIVES.
    Geographies
    Not indicated
    Dates
    Jan 1, 2020 – Dec 31, 2020
    Source
    990
    No causes provided
    No populations provided
    –
    $183.1K
  • Program 2 [2020]
    IN 2020, RCRF CONTINUED TO CREATE STRATEGIC INVESTMENTS AND COLLABORATIONS THAT CATALYZED EFFECTIVE RESEARCH AND ACCELERATED THE DEPLOYMENT OF PROMISING THERAPIES.
    Geographies
    Not indicated
    Dates
    Jan 1, 2020 – Dec 31, 2020
    Source
    990
    No causes provided
    No populations provided
    –
    –
  • PPOI Advanced Cancer Initiative
    PPOI (FORMERLY H37) IS ON A MISSION TO CREATE EXCEPTIONAL OUTCOMES FOR INDIVIDUALS FACING ADVANCED CANCER BY PUSHING THE BOUNDARIES OF SCIENCE, RESEARCH, AND CLINICAL INNOVATIONS. WORKING IN DEEP PARTNERSHIP WITH A SMALL GROUP OF CLIENTS WITH ADVANCED CANCERS, PPOI EXPLORES THE DETAILED MOLECULAR AND CLINICAL CHARACTERISTICS OF INDIVIDUAL CLIENT'S DISEASE TO HELP THEM AND THEIR CLINICAL TEAM MAKE MORE DATA-INFORMED DECISIONS ABOUT THEIR TREATMENT JOURNEY. WE HAVE ALREADY SEEN THE SUCCESS OF THIS PROGRAM IN THE FIRST PERSONALIZED VACCINE VALIDATED WITH MASS SPECTROMETRY IN THE COUNTRY AS WELL AS DAILY WINS AS WE WORK TO NAVIGATE THROUGH THIS COMPLEX AND EVER-CHANGING LANDSCAPE ON BEHALF OF THESE PATIENTS.
    Geographies
    Not indicated
    Dates
    Jan 1, 2023 – Dec 31, 2023
    Source
    990
    No causes provided
    No populations provided
    –
    $889.9K
Programs
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)
Terms of Use
Privacy Policy